Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

← Glioblastoma

Glioblastoma: treatment map

Standard care plus compounds studied in the literature, organized by clinical readiness.

Educational only. This is not medical advice and not a recommendation. Confirm anything here with your oncology team.

Treatment map: Glioblastoma

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

45
Interventions
0
Standard of care
37
Tested in people
0
Lab / animal
1
Named in lit.
8
Classes
Standard of care (0) Guideline option (7) Tested in people (37) Lab / animal only (0) Named in the literature (1)

Tested in people, by trial phase: Phase II ×1 · phase not reported ×36

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
7
—
1
Radiotherapy
—
—
3
—
—
Chemotherapy
—
5
3
—
—
Targeted therapy
—
1
9
—
—
Immunotherapy
—
—
4
—
—
Repurposed drugs
—
—
1
—
—
Supplements & natural agents
—
—
5
—
—
Other
—
1
5
—
—

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (7)
Chemotherapy
TemozolomideAdjuvant (after surgery) · IDH-wildtype
FDA-approved for this cancer.
—Guideline option
temozolomideAdjuvant (after surgery)
FDA-approved for this cancer.
—Guideline option
TemozolomideMaintenance
FDA-approved for this cancer.
—Guideline option
temozolomideFirst-line (advanced disease)
FDA-approved for this cancer.
—Guideline option
TemozolomideAdjuvant (after surgery) · methylation at the O6-methylguanine-DNA methyltransferase (MGMT) promoter in cancer DNA
FDA-approved for this cancer.
—Guideline option
Targeted therapy
Bevacizumab
FDA-approved for this cancer.
—Guideline option
Other
Temozolomide
FDA-approved for this cancer.
—Guideline option
Investigational & adjunct compounds — detail (38)
Phase II trial (1)
Pembrolizumaboff-label
Meta-analysis (36)
?5-aminolevulinic acid (5-ALA) fluorescence-guided surgeryArsenicoaxitinibBest supportive careBIBR1532Butylidenephthalide (BP)CostunolideCRISPRi TERT silencingcurcumindendritic cell vaccineDoxorubicinoff-labelEpigallocatechin gallate (EGCG)Eribulin· TERT mutationsgenisteinGraphene quantum dots (GQDs)· Neoadjuvant (before surgery)gross total resection (GTR)Hypofractionated radiotherapy plus temozolomideIL-12-armed oncolytic herpes simplex virus (oHSV:IL-12)intraoperative radiotherapylomustine (CCNU)Maximal safe surgical resection· Adjuvant (after surgery)MST-312MZ-5-156 (GH-RH antagonist)oncolytic herpes simplex virus (oHSV)plumbaginRadiotherapy· Adjuvant (after surgery)RadiotherapyResveratroloff-labelsupervised aerobic and resistance exercise· Adjuvant (after surgery)Supratotal resection (SpTR)SuraminThymoquinonetrichostatin A (TSA)Tumor Treating Fields (alternating electric field therapy)· First-line (advanced disease)tumor treating fields (TTF)
Named in the literature
Surgical resection (extent of resection)· First-line (advanced disease)

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.